Reassessing the two-year rodent carcinogenicity bioassay: A review of the applicability to human risk and current perspectives

Regulatory Toxicology and Pharmacology

Volumn 68, Issue 1, 2014, Pages 108-118

  Marone, Palma Ann ^a   Hall, William C ^b   Hayes, A Wallace ^c  

^a Product Safety Laboratories   (United States)

^b Hall Consulting Inc ^*  (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

2 Year carcinogenicity; Genotoxicity; Human risk assessment; Prediction

Indexed keywords

2 YEAR RODENT CARCINOGENICITY BIOASSAY; ANIMAL TESTING ALTERNATIVE; ANIMAL USE; ARTICLE; BIOASSAY; CARCINOGEN TESTING; CARCINOGENICITY; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; EXPERIMENTAL ANIMAL WELFARE; GENOTOXICITY; HEALTH HAZARD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDUSTRIAL WASTE; INTERMETHOD COMPARISON; NONHUMAN; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; RODENT;

2-YEAR CARCINOGENICITY; GENOTOXICITY; HUMAN RISK ASSESSMENT; PREDICTION;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; HUMANS; MICE; MODELS, BIOLOGICAL; RATS; RISK ASSESSMENT;

EID: 84890816406     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.11.011     Document Type: Article

References (239)

1. Aardema M.J., Barnett B.C., Khambatta Z., Reisinger K., Ouedraogo-Arras G., Faquet B., Ginestet A.C., Mun G.C., Dahl E.L., Hewitt N.J., Corvi R., Curren R.D. International prevalidation of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility. Mutat. Res. 2010, 701:123-131.
2. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen K.E., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F.Y., Boobi S.A., Brandon E., Bremer S., Brochard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S.B., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfuhler S., Pfrakonkem P., Piersma A., Poth A., Prieto P., Repetto G., Roqiers B., Schoeters G., Schwarz M., Serafimova R., Tahti H., Testai E., van Delft J., van Loveren H., Vinken M., Worth A., Zaldivar J.M. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 2011, 85:367-485.
3. Agostini M., Schoenmakers E., Mitchell C., Szatmari I., Savage D., Smith A., Rajanayagam O., Semple R., Luan J., Bath L., Zalin A., Labib M., Kuma R.S., Simpson H., Blom D., Marais D., Schwabe J., Barroso I., Trembath R., Wareham N., Nagy L., Gurnell M., O'Rahilly S., Chatterjee K. Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell. Metabol. 2006, 4:303-311.
4. Alden C.L. A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol. Pathol. 1996, 24:722-725.
5. Alden C.L., Lynn A., Bourdeau A., Morton D., Sistare F.D., Kadambi V.J., Silverman L. A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk. Vet. Pathol. 2011, 48:772-784.
6. Alison R.H., Capen C.C., Prentice D.E. Neoplastic lesions of questionable significance to humans. Toxicol. Pathol. 1994, 22:179-186.
7. Allen D.G., Pearse G., Haseman J.K., Maronpot R.R. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 2004, 32:393-401. 10.1080/01926230490440934.
8. Cassarett and Doull's Toxicology: The Basic Science of Poisons 1991, Pergamon Press, New York, p. 1033. fourth ed. M.O. Amdur, J. Doull, C.D. Klaassen (Eds.).
9. Ames B., Lee F., Durston W. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl. Acad. Sci. 1973, 70:782-786.
10. Ashby J. Expectations for transgenic rodent cancer bioassay models. Toxicol. Pathol. 2001, 29:177-182.
11. Benigni R., Netzeva T.I., Benfenati E., Bossa C., Franke R., Helma C., Holzebos E., Merchan T.C., Richard A., Woo Y.T., Yang C. The expanding role of predictive toxicology: an update on the (Q)SAR models for mutagens and carcinogens. J. Environ. Sci. Health C Environ. Carc. Ecotoxicol. Rev. 2007, 25:53-97.
12. Benigni R., Bossa C. Alternative strategies for carcinogenicity assessment: an efficient and simplified approach based on in vitro mutagenicity and cell transformation assays. Mutagenesis 2011, 26:455-460.
13. Benigni R., Bossa C. Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. Chem. Rev. 2011, 111:2507-2536.
14. Benigni R., Bossa C., Giuliani A., Tcheremenskaia O. Exploring in vitro/in vivo correlations: lessons learned from analyzing phase I results of U.S.EPA's ToxCast project. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2010, 28:272-286.
15. Benigni R., Bossa C., Tcheremenskaia O., Giuliani A. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays. Exp. Opin. Drug Metab. Toxicol. 2010, 6:1-11.
16. Benz, D.R., Matthews, E.J., Kruhlak, N.L., Frid, A.A., Minnier, B.L., Contrera, J.F., 2007. Toxicological and clinical computational analysis by the Informatics and Computational Safety Analysis staff of the US FDA/CDER. AATEX 14 Special Issue. Proc. 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Japan, pp. 463-467.
17. Berwald Y., Sachs L. In vitro transformation of normal cells to tumour cells by carcinogenic hydrocarbons. J. Natl. Canc. Inst. 1965, 35:641-661.
18. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., Willcocks D., Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 2006, 36:781-792.
19. Borman, S., 2013. Drug design on the fast track. Chm. Eng. News 7:26.
20. Bredel M., Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 2004, 5:262-275.
21. Bucher J.R. The national toxicology program rodent bioassay: designs, interpretations and scientific contributions. Ann. N.Y. Acad. Sci. 2002, 982:198-207.
22. Bucher J.R., Portier C. Human carcinogenic risk evaluation, Part V: the national toxicology program vision for assessing the human carcinogenic hazard of chemicals. Toxicol. Sci. 2004, 82:363-366.
23. Butterworth B.E., Conolly R.B., Morgan K.T. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett. 1995, 93:129-146.
24. Cheon, D.J., Orsulic, S., 2011. Annual reviews of pathology: mechanisms of disease 6, 95-119. [Online] Available at: DOI: 10.1146/annurev.pathol.3.121806.154244 (Accessed on 20.08.2013). http://www.ncbi.nlm.nih.gov/pubmed/20936938.
25. Chu K.C., Cipriano C., Ward J.M. Factors in the evaluation of 200 national cancer institute carcinogen bioassays. J. Tox. Environ. Health 1981, 8:251-280.
26. Cogliano V.J., Baan R.A., Straif K., Grosse Y., Secretan M.B., El Ghissassi F., Kleihues P. The science and practice of carcinogen identification and evaluation. Environ. Health Perspect. 2004, 112:1269-1274.
27. Cohen S.M., Arnold L.L., Cano M., Ito M., Garland E.M., Shaw R.A. Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. Carcinogenesis 2000, 21:783-792.
28. Cohen S.M., Robinson D., MacDonald J. Alternative models for carcinogenicity testing. Toxicol. Sci. 2001, 64:14-19.
29. Cohen S.M. Human carcinogenic risk evaluation: an alternative approach to the 2-year rodent bioassay. Toxicol. Sci. 2004, 80:225-229.
30. Cohen S.M. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the 2-year bioassay is no longer necessary. Toxicol. Pathol. 2010, 38:487-501.
31. Cohen S.M. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors. Asian Pac. J. Cancer Prev. 2010, 11:15-17.
32. Cohen S.M. Urinary bladder carcinogenesis by DNA reactive and non-reactive chemicals: non-linearities and thresholds. Genes Environ. 2012, 34:165-170.
33. Combes R., Schechtman L., Stokes W.S., Blakey D. The international symposium on regulatory testing and animal welfare: recommendations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing. ILAR J. 2002, 43:S112-S117.
34. Contrera J.F., Jacobs A.C., DeGeorge J.J. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul. Toxicol. Pharmacol. 1997, 25:130-145.
35. Contrera J.F., DeGeorge J.J. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ. Health Perspect. 1998, 106:71-80.
36. Council of Canadian Academies, 2012. Integrating emerging technologies into chemical safety assessment, Ottawa, Canada: the expert panel on the integrated testing of pesticides. [Online] Available at: (Accessed on 8.07.2013). http://www.scienceadvice.ca/uploads/eng/assessments.
37. Countryman P.I., Heddle J.A. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res. 1976, 41:321-322.
38. Creton S., Aardema M.J., Carmichael P.L., Harvey J.S., Martin F.L., Newbold R.F., O'Donovan M.R., Pant K., Poth A., Sakai A., Sasaki K., Scott A.D., Schechtman L.M., Shen R.R., Tanaka H., Yasaei H. Meeting Report. Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs. Mutagenesis 2012, 27:93-101.
39. Crissman J.W., Goodman D.G., Hildbrandt P.K., Maronpot R.R., Prater D.A., Riley J.H., Seaman W.J., Thake D.C. Best practices guideline: toxicological histopathology. Toxicol. Pathol. 2004, 32:126-131.
40. Cronin M.T.D., Jaworska J.S., Walker J.D., Comber M.H.I., Watts C.D., Worth A.P. Use of QSARs in international decision-making frameworks to predict health effects of chemical substances. Environ. Health Perspect. 2003, 111:1391-1401.
41. D'Aguanno, W., 1973. Drug-toxicity evaluation: preclinical aspects. In: FDA Introduction to Total Drug Quality, DHEW Publication (FDA), 74-3006, pp. 35-40.
42. Danesi R., De Braud F., Fogli S., De Pasa T.M., Di Paolo A., Curigliano G., Del Tacca M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharm. Rev. 2003, 55:57-103.
43. Davies T.S., Lynch B.S., Monro A.M., Munro I.C., Nestmann E.R. Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs. Food Chem. Toxicol. 2000, 38:219-235.
44. De Camargo, J.L.V., 2013. Chemical carcinogenesis - mode of action to inform quantitative human risk. BMC Proc. 2013, 7(Suppl. 2), K10 [Online] Available at: doi: 10.1186/1753-6561-7-S2-K10 (Accessed on 20.08.2013). http://www.biomedcentral.com/1753-6561/7/S2/K10.
45. Dellarco V., Baetcke K. A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data. Toxicol. Sci. 2005, 86:1-3. 10.1093/toxsci/kfi133.
46. Devor, D.E., Henneman, J.R., Kurata, Y., Rehm, S., Weghorst, C.M., Ward, J.M., 1994. Pathology procedures in laboratory animal carcinogenesis studies. In: Waalkes, M.P., Ward, J.M., (Eds.), Carcinogenesis, Raven Press, New York, pp. 429-466.
47. Dix D.J., Houck K.A., Martin M.T., Richard A.M., Setzer R.R., Kavlock R.J. The ToxCast Program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 2007, 95:5-12.
48. Dix D.J., Houck K.A., Judson R.S., Kleinstreuer N.C., Knudson T.B., Martin M.T., Reif D.M., Richard A.M., Shah I., Sipes N.S., Kavlock R.J. Incorporating biological, chemical, and toxicological knowledge into predictive models of toxicity. Toxicol. Sci. 2012, 130:440-441.
49. Dua P.N., Jackson B.A. Review of pathology data for regulatory purposes. Toxicol. Pathol. 1988, 16:443-450.
50. Dueñas, M., Santos, M., Aranda, J.F., Bielza, C., Martínez-Cruz, A.B., Lorz, C., Taron, M., Ciruelos, E.M., Rodríguez-Peralto, J.L., Martín, M., Larrañaga, P., Dahabreh, J., Stathopoulos, G.P., Rosell, R., Paramio, J.M., García-Escudero, R., 2012. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One 7(8), e42494. [Online] Available at: http://0-www.ncbi.nlm.nih.gov.elis.tmu.edu.tw/pubmed/22880004. doi: 10.1371/journal.pone.0042494 (Accessed on 19.08.2013).
51. Ennever F.K., Lave L.B. Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul. Tox. Pharm. 2003, 38:52-57.
52. Enzmann H., Bomhard E., Iatropoulos M., Ahr H.R., Schlueter G., Williams G.M. Short- and intermediate-term carcinogenicity testing- a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay. Food Chem. Toxicol. 1998, 36:979-995.
53. Enzmann H., Iatropoulos M., Brunnemann K.D., Bonhard E., Ahr H.J., Schlueter G., Williams G.M. Short- and intermediate-term carcinogenicity testing - a review. Part 2: available experimental models. Food Chem. Toxicol. 1998, 36:997-1013.
54. Ettlin R.A., Kuroda J., Plassmann S., Prentice D.E. Successful drug development despite adverse preclinical findings. Part1: processes to address issues and most important findings. J. Toxicol. Pathol. 2010, 23:189-211.
55. Ettlin R.A., Kuroda J., Plassmann S., Hayashi M., Prentice D.E. Successful drug development despite adverse preclinical findings. Part 2: examples. J. Toxicol. Pathol. 2010, 23:213-234.
56. Ettlin R.A. Toxicologic pathology in the 21st century. Toxicol. Pathol. 2012, doi: 0192623312466192 (Online 9 November 2012).
57. European Commission, 2010a. Draft report on alternative (non-animal) methods for cosmetics testing: Current status and future prospects - 2010. Health and consumers directorate-general Consumer Affairs, Cosmetics and Medical Devices, Brussels, Belgium. [Online] Available at: (Accessed on 14.03.2013). http://europa.eu/generalreport/pdf/rg2009_en.pdf.
58. European Commission, 2010b. Scientific report submitted to EFSA applicability of QSAR analysis to the evaluation of the toxicological relevance of metabolites and degradates of pesticide active substances for dietary risk assessment. Prepared by Computational Toxicology Group, Institute for Health & Consumer Protection, European Commission - Joint Research Centre, Ispra, Italy.
59. European Commission, 2013. Full EU ban on animal testing for cosmetics enters into force. Press Release. Reference: IP/13/210. Brussels, 11 March 2013. [Online] Available at: (Accessed on 5.05.2013). http://europa.eu/rapid/press-release_IP-13-210_en.htm.
60. EFSA (European Food Safety Authority) Scientific opinion on genotoxicity testing strategies applicable to food and food safety assessment. EFSA Scientific Committee. EFSA J. 2011, 9:2379.
61. EFSA Guidance on conducting 90-day repeated dose oral toxicity study in rodents on whole food/feed. EFSA Scientific committee. EFSA J. 2011, 9:2438.
62. ESTP (European Society of Toxicologic Pathology), 2005. Regarding Society of Toxicologic Pathology (STP) "revision of standardized nomenclature for lesions in the rat and mouse". Unpublished letter from W. Kauffmann, President of ESTP to Nancy Everds, President STP, 19 September 2005. [Online] Available at: (Accessed on 11.04.2013). http://www.eurotoxpath.org/wk1752_letter_to_STP.pdf.
63. Faccini J.M., Butler W.R., Friedmann J.C., Hess R., Reznik G.K., Ito N., Hayashi Y., Williams G.M. IFASTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay. Exp. Toxicol. Pathol. 1992, 44:443-456.
64. FDA (Food and Drug Administration), 1978. Good laboratory practice for non-clinical laboratory studies. (Source: 43 FR 60013; as amended at 52 FR 33779). 21 CFR Parts 58.1 - 58.219.
65. FDA, 2000a. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.C.6. Carcinogenicity studies with rodents.
66. FDA, 2000b. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.B.1. General guidelines for designing and conducting toxicity studies.
67. FDA, 2000c. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.C.3a. Short-term toxicity studies with rodents.
68. FDA, 2000d. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.C.9a. Guidelines for reproductive studies.
69. FDA, 2000e. Toxicological principles for the safety assessment of food ingredients: FDA Redbook 2000: Section IV.C.9b. Guidelines for developmental toxicity studies.
70. FDA, 2011. Food Safety Modernization Act. 111th Congress Public Law 353. Amendment to the Federal Food, Drug, and Cosmetic Act.
71. FDA Department of health and human services, ICH; proposed change to rodent carcinogenicity testing of pharmaceuticals; request for comments. Docket No. FDA-2013-N-0222. Fed. Reg. 2013, 78:16681-16684.
72. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., 2010. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC cancer base no. 10. Lyon, France. [Online] Available at: (Accessed on 3.04.2013). http://globocan.iarc.fr/.
73. Fratev, F., Benfanati, E., 2008. A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals. J Mol. Graph Mod. 27, 147-160. [Online] Available at: doi: 10.1016/j.jmgm.2008.04.004. Epub 10 April 2008 (Accessed on 15.08.2013). http://www.ncbi.nlm.nih.gov/pubmed/18495507.
74. Freedman D.A., Gold L.S., Lin L.H. Concordance between rats and mice in bioassays for carcinogenesis. Regul. Toxicol. Pharmacol. 1996, 23:225-232.
75. French J.E., Spalding J.W., Dunnick J.K., Tice R.R., Furedi-Machacek M., Tennant R.W. The use of transgenic animals in cancer testing. Inhal. Toxicol. 1999, 11:541-544.
76. Gaylor D.W. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?. Regul. Toxicol. Pharmacol. 2004, 41:128-133.
77. Gaylor, D.W., Chen, J.J., Kodel, R.L., 1985. Experimental design of bioassays for screening and low dose extrapolation. Risk Anal. 5, 9-16. Cited in Rhomberg et al., 2007.
78. Gold L.S., Slone T.H., Manley N.B., Bernstein L. Target organs in chronic bioassays of 533 chemical carcinogens. Environ. Health Perspect. 1991, 93:233-246.
79. Gold L.S., Slone T.H., Ames B.N. What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Met. Rev. 1998, 30:359-404.
80. Gold L.S., Manley N.B., Slone T.H., Rohrbach L. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993-1994 and by the national toxicology program in 1995-1996. Environ. Health Perspect. 1999, 107:527-600.
81. Goldenthal E. Current views on safety evaluation of drugs. FDA Papers 1968, 2:13-18.
82. Gori G.B. Regulatory forum opinion piece: long-term bioassays: is the end near?. Toxicol. Pathol. 2013, 41:805-807.
83. Gulezian D., Jacobson-Kram D., McCullough C.B., Olson H., Recio L., Robinson D., Storer R., Tennant R., Ward J.M., Neumann D.A. Review article: use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol. Pathol. 2000, 28:482-499.
84. Gunter V.P., Waldrep J.C., Guo J.J., Selting K., Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. AntiCancer Res. 2010, 30:3557-3564.
85. Guyton K.Z., Barone S., Brown R.C., Euling S.Y., Jinot J., Makris S. Mode of action frameworks: a critical analysis. J. Toxicol. Environ. Health B Crit. Rev. 2008, 11:16-31. 10.1080/10937400701600321.
86. Hartung T., Blaauboer B.J., Bosgra S., Carney E., Coenen J., Conolly R.B., Corsini E., Green S., Faustman E.M., Gaspari A., Hayashi M., Hayes A.W., Hengstler J.G., Knudsen L.E., Knudsen T.B., McKim J.M., Pfaller W., Roggen E.L. An expert consortium review of the ec-commissioned report "alternative (non-animal) methods for cosmetics testing: current status and future prospects - 2010". ALTEX 2011, 28:183-209.
87. Haseman J.K., Elwell M.R. Evaluation of false positive and false negative outcomes in NTP long-term rodent carcinogenicity studies. Risk Anal. 1996, 16:813-820.
88. Haseman J.K., Lockhart A. The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. Fund. Appl. Toxicol. 1994, 22:382-391.
89. Hayes A.W., Dayan A.D., Hall W.C., Kodell R.L., Williams G.M., Waddell W.D., Slesinski R.S., Kruger C.L. A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients. Regul. Toxicol. Pharmacol. 2011, 60:S1-S34.
90. Heddle J.A. A rapid in vivo test for chromosomal damage. Mutat. Res. 1973, 18:187-190.
91. Hendrix M.J., Seftor E.A., Seftor R.E., Kasemeier-Kulesa J., Kulesa P.M., Postovit L.M. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 2007, 7:246-255.
92. Hoffman R.M. In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J. Clin. Lab. Anal. 1991, 5:133-143.
93. Huff J. Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini Foundation and the National Toxicology Program: in tribute to Cesare Maltoni and David Rall. Ann. N.Y. Acad. Sci. 2002, 982:208-230.
94. Huff J., Jacobson M.F., Davis D.L. The limits of the 2-year bioassay exposure regimens for identifying chemical carcinogens. Environ. Health Perspect. 2008, 116:1439-1442.
95. Huff, J.E., Haseman, J.K., McConnel, E.E., Moore, J.A., 1986. The National Toxicity Program, toxicology data evaluation techniques and long-term carcinogenesis studies. In: Loyd, W, E., (Ed.), Safety Evaluation of Drugs and Chemicals, Hemisphere, Washington, DC, pp. 411-446.
96. IARC (International Agency for Research on Cancer), 1980. Long-term and short-term screening assays for carcinogens: a critical appraisal. IARC Monographs 83/001 Lyon, France. [Online] Available at: (Accessed on 18.03.2013). http://legacy.library.ucsf.edu/documentStore/m/a/u/mau67e00/Smau67e00.pdf.
97. IARC (International Agency for Research on Cancer) Overall evaluations of carcinogenicity: an updating of IARC monographs, vols. 1-42 1987, IARC Press, Lyon, France.
98. IARC, 1999. The use of short- and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. In: McGregor, D.B., Rice, J.M., Venit, S., (Eds.), IARC Scientific Publications. No. 146, Lyon, France. [Online] Available at: (Accessed on 27.03.2013). http://monographs.iarc.fr/ENG/Publications/index1.php.
99. IARC, 2006. Report of the advisory group to review the amended preamble to the IARC monographs (IARC Int. Rep. No. 06/001). IARC monographs of the evaluation of the carcinogenic risk to humans: Preamble to the IARC monographs, Lyon, France.
100. ICH (International Conference on Harmonization), 1993. Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. Guideline S5(R2). [Online] Available at: (Accessed on 16.08.2013). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2__Guideline.pdf.
101. ICH, 1996. The need for carcinogenicity studies of pharmaceuticals. Guideline S1A. CPMP/ICH/140/95.
102. ICH, 1998. Carcinogenicity: testing for carcinogenicity of pharmaceuticals. Guideline S1B. CPMP/ICH/299/95.
103. ICH, 2005. Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. Guideline S5 (R2). CPMP/ICH/386/95.
104. ICH, 2006. Immunotoxicity studies for human pharmaceuticals. Guideline S8. CHMP/167235/2004.
105. ICH, 2008a. Dose selection for carcinogenicity studies. Guideline S1C(R2) center for drug evaluation and research; center for biologics evaluation and research: ICH revision 1. Fed. Reg. 60, 11278-11281, Addendum 62:64260.
106. ICH, 2008b. Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Guideline M3(R2). CPMP/ICH/286/95.
107. ICH, 2011. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Guideline S6 (R1). EMA/CHMP/ICH/731268/1998.
108. ICH, 2012a. Pre-clinical safety evaluation of biotechnology-derived pharmaceuticals. Guideline S6(R1) Addendum. Center for drug evaluation and research; center for biologics evaluation and research: [Online] Available at: (Accessed on 16.08.2013). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf.
109. ICH, 2012b. Genotoxicity testing and data interpretation for pharmaceuticals intended for human use. Guideline S2 (R1). EMA/CHMP/ICH/126642/2008.
110. ICH Regulatory notice on changes to core guideline on rodent carcinogenicity testing of pharmaceuticals. Guideline S1. EMA/CHMP/ICH/752486/2012. Infante PF. (1993). Use of rodent carcinogenicity test results for determining potential cancer risk to humans. Environ. Health Perspect. 2012, 101:143-148.
111. IPCS (International Programme for Chemical Safety), 2007. The IPCS Harmonization Project. February 2007 Newsletter. [Online] Available at: (Accessed on 20.08.2013). http://www.who.int/ipcs/methods/harmonization/feb07newsletter.pdf.
112. Javier R.T., Butel J.S. The history of tumor virology. Cancer Res. 2008, 68:7693-7706.
113. Jacobs A. Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing?. Toxicol. Sci. 2005, 88:18-23.
114. Jacobs A.C., Hatfield K.P. History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet. Pathol. 2013, 50:324-333.
115. Jacobson-Kram D.K. Cancer risk assessment approaches at the FDA/CDER: is the era of the 2-year bioassay drawing to a close?. Toxicol. Pathol. 2010, 38:169-170.
116. Jacobson-Kram, D., Sistare, F.D., Jacobs, A.C., 2004. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol. Pathol. 32(S1), 49-52.
117. Jena G.B., Kaul C.L., Ramarao P. Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: a review of current status. Ind. J. Pharmacol. 2005, 37:209-222.
118. Kavlock R., Chandler K., Houck K., Hunter S., Judson R., Kleinstreuer N., Knudsen T., Martin M., Padilla S., Reif D., Richard A., Rotroff D., Sipes N., Dix D. Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol. 2012, 25:1287-1302.
119. Keenan C., Elmore S., Franke-Carroll S., Kemp R., Kerlin R. Best practices for use of historical control data of proliferative rodent lesions. Toxicol. Pathol. 2009, 37:679-693.
120. Kharkar P.S. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. Curr. Top. Med. Chem. 2010, 10:116-126.
121. Kirkland D., Aardema M., Henderson L., Muller L. Evaluation of a battery of three in vitro genotoxicity tests to determine rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584:1-256.
122. Kirkland D., Kasper P., Muller L., Corvi R., Speit G. Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow up to an ECVAM workshop. Mutat. Res. 2008, 653:99-108.
123. Kirkland D., Reeve L., Gatehouse D., Vanparys P. A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. Mutat. Res. 2011, 271:27-73.
124. Kirsch-Volders M., Decordier I., Elhajouji A., Plas G., Aardema M.J., Fenesh M. In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. Mutagenesis 2011, 26:177-184.
125. Klaunig J.E., Babich M.A., Baetcke K.T., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp P.A. PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33:655-780.
126. Lambert I.B., Singer T.M., Boucher S.E., Douglas G.R. Detailed review of transgenic rodent mutation assays. Mutat. Res. 2005, 590:1-280.
127. Leblanc B. Pathology and tissue sampling protocols for rodent carcinogenicity studies: time for revision. Toxicol. Pathol. 2000, 28:628-633.
128. Lehman A.J., Laugh E.P., Woodward G., Draize J.H., Fitzhugh O.G., Nelson A.A. Procedures for the appraisal of the toxicity of chemicals in food. Food Drug Cosmet. Law Q 1949, 4:412-434.
129. Lehman A.J., Patterson W.I., Davidow B., Hagan E.C., Woodard G., Laug E.P., Frawley J.P., Fitzhugh G., Bourke A.R., Draize J.H., Nelson A.A., Vos B.J. Procedures for the appraisal of the toxicity of chemicals in food. Food Drug Cosmet. Law J. 1955, 10:679-748.
130. Locke, P., Goldberg, A.M., 2006. Alternatives in toxicology. In: Green, S.A., (Ed.), Toxicology and the Regulatory Process: Alternatives to Animals in Toxicology, Taylor & Francis, Group, New York, pp. 245-257.
131. Long, M.E., 2007. Predicting carcinogenicity in humans: the need to supplement animal-based toxicology. AATEX Special Issue. In: Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences, Tokyo, Japan, 14, pp. 553-559.
132. Long, P.H., Elwell, M., Harris, R.K., Leininger, J.R., McKinney, L.A., Moch, R.W., Slayter, M.V., 1992. Guides for toxicologic pathology. In: Standardized System of Nomenclature and Diagnostic Criteria. STP/ARP, AFIP, Washington DC, p. 3.
133. MacDonald J., French J.E., Gerson R.J., Goodman J., Inoue T., Jacobs A., Kasper P., Keller D., Lavin A., Long G., McCullough B., Sisate R.D., Sorer R., van der Laan J.W. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. the alternatives to carcinogenicity testing committee ILSI-HESI toxicol. Science 2004, 77:188-194.
134. Macarron R. Critical review of the role of HTS in drug discovery. Drug Discov. Today 2006, 11:277-279.
135. Mackay, C., 2013. Cosmetics Europe regrets European Union decision to proceed with marketing ban: science gaps not respected. Cosmetics Europe Press Release, Brussels, 11 March 2013.
136. Magnuson B.A., Burdock G.A., Doull J., Kroes R.M., Marsh G.M., Pariza M.W., Spencer P.S., Waddell W.J., Walker R., Williams G.M. Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies. Crit. Rev. Toxicol. 2007, 37:629-727.
137. Maltoni C., Soffritti M., Belpoggi F. The scientific and methodological bases of experimental studies for detecting and quantifying carcinogenic risks. Eur. J. Oncol. 1999, 3:5-10.
138. Manuppello J., Willett C. Longer rodent bioassay fails to address 2-year bioassay's flaws. Environ. Health Perspect. 2008, 116:A516-A517.
139. Martin M.T., Knudsen T.B., Judson R.S., Kavlock R.J., Dix D.J. Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program. Syst. Biol. Reprod. Med. 2012, 58:3-9.
140. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. 1975, 72:5135-5139.
141. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
142. Melnick R.L., Thayer K.A., Bucher J.R. Conflicting views on chemical carcinogenesis arising from the design and evaluation of rodent carcinogenicity studies. Environ. Health Perspect. 2008, 116:130-135.
143. Miller J.A., Miller E.C. The carcinogenic aminoazo dyes. Adv. Cancer Res. 1953, 1:339-396.
144. Monro A.M. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents?. Exp. Toxicol. Pathol. 1996, 48:155-166.
145. Morton D., Alden C.L., Roth A.J., Usui T. The Tg rasH2 mouse in cancer hazard identification. Toxicol. Pathol. 2002, 30:139-146.
146. Morton D., Bourcier T., Alden C.L. Improving carcinogenicity assessment. Toxicol. Pathol. 2013, 41:263-270. Epub 17 October 2012. 10.1177/0192623312464310.
147. Nakazawa T., Kurokawa M., Kimura K., Wakata A., Hisada S., Inoue T., Sagami F., Heidel S.M., Kawakami K., Shinoda K., Onoder H., Kumagai Y., Ohno Y., Kawamura N., Yamazaki T., Inoue T. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance. J. Toxicol. Sci. 2008, 33:277-282.
148. NCI (National Cancer Institute), 1976. Guidelines for carcinogen bioassay in small rodents. In: DHEW Publ. (NIH), Bethesda, MD, pp. 76-80, 1-65.
149. NIPHE (National Institute for Public Health and the Environment), 2012. Prediction of carcinogenic potential of substances using repeated dose toxicity data. Ministry of Health, Welfare and Sport. RIVM Report 340700006/2012. [Online] Available at: http://www.nkca.nl/object_binary/o5169_RIVM-report-340700006[1].pdf (Accessed 15.08.2013).
150. NIOSH (National Institute for Occupational Safety and Health), 1983. Health hazard evaluation report no. HETA 82-146-1388, Boeing Verol Co. Phil. PA, National Institutes for Occupational Safety and Health, Washington, DC.
151. NRC (National Research Council), 1993. Use of the maximum tolerated dose in animal bioassays for carcinogenicity. In: Goldstein, B., et al., (Eds.), Issues in Risk Assessment. National Academy Press, Washington, DC, pp. 15-83.
152. NTP (National Toxicology Program), Specifications for the conduct of studies to evaluate the toxic and carcinogenic potential of chemical, biological and physical agents in laboratory animals for the National Toxicology Program (NTP) 2006, National Toxicology Program, Research Triangle Park, NC.
153. NTP, 2013. Long-term study reports and abstracts. [Online] Available at: http://ntp.niehs.nih.gov/?objectid=D16D6C59-F1F6-975E-7D23D1519B8CD7A5 (Accessed on 15.05.2013).
154. Nuffield Council on Bioethics, 2005. Animal use in toxicity studies. In: The Ethics of Research Involving Animals. Oxford University Press, London, UK, pp. 154-167. [Online] Available at: www.nuffieldbioethics.org/go/ourwork/animalresearch/introduction (Accessed on 27.03.2013).
155. OECD (Organization for Economic Cooperation and Development). 1983. Guideline for the testing of chemicals. Section 4 (Part 415): health effects: one-generation reproduction toxicity study.
156. OECD, 1995. Guideline for the testing of chemicals. Section 4 (Part 421): health effects: reproduction/developmental toxicity screening test.
157. OECD, 1996. Guideline for the testing of chemicals. Section 4 (Part 422): health effects: combined repeated dose toxicity study with the reproduction/developmental screening test.
158. OECD, 1997a. Guideline for the testing of chemicals. Section 4 (Part 424): health effects: neurotoxicity study in rodents.
159. OECD, 1997b. Guideline for the testing of chemicals. Section 4 (Part 474): health effects: mammalian erythrocyte micronucleus test.
160. OECD, 1998. Guideline for the testing of chemicals. Section 4 (Part 408): health effects: repeated dose 90-day oral toxicity study in rodents.
161. OECD, 2001a. Guideline for the testing of chemicals. Section 4 (Part 414): health effects: prenatal developmental toxicity study.
162. OECD, 2001b. Guideline for the testing of chemicals. Section 4 (Part 416): health effects: two-generation reproduction toxicity study.
163. OECD, 2008. Guideline for the testing of chemicals. Section 4 (Part 407): health effects: repeated dose 28-day oral toxicity study in rodents.
164. OECD, 2009a. Guideline for the testing of chemicals. Section 4 (Part 451): health effects: carcinogenicity studies.
165. OECD, 2009b. Guideline for the testing of chemicals. Section 4 (Part 452): health effects: chronic toxicity studies.
166. OECD, 2009c. Guideline for the testing of chemicals. Section 4 (Part 453): health effects: combined chronic toxicity/carcinogenicity studies.
167. OECD, 2011. Guideline for the testing of chemicals. Section 4 (Part 443): health effects: extended one-generation reproductive toxicity study.
168. OECD, 2012. Draft OECD guideline for the testing of chemicals: rodent alkaline single cell gel electrophoresis (Comet) assay. [Online] Available at: http://www.oecd.org/env/ehs/testing/OECD_draft_Comet[1].pdf (Accessed on 15.08.2013).
169. Parsons A.B., Lopez A., Givoni I.E., Williams D.E., Gray C.A., Porter J., Chua G., Sopko R., Brost R.E., Ho C.H., Wang J., Ketela T., Brenner C., Brill J.A., Fernandez E., Lorenz T.C., Payne G.S., Ishihara S., Ohya Y., Andrews B., Hughes T.R., Frey B.J., Graham T.R., Anderson R.J., Boone C. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 2006, 126:611-625. 10.1016/j.cell.2006.06.040.
170. Pastoor, T., Rose, P., Lloyd, S., Peffer, R., Green, T., 2005. Thiamethoxam induced mouse liver tumors and their relevance to humans, Part 3: Weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors. Toxicol. Sci. 86.
171. Pastoor T., Stevens J. Historical perspective of the cancer bioassay. Scand. J. Environ. Health 2005, 31:129-140.
172. Politi K., Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol. 2011, 29:2273-2281.
173. Portier C., Hoel D. Optimal design of the chronic animal bioassay. J. Toxicol. Environ. Health 1983, 12:1-19.
174. Poth A., Heppenheimer A., Bohnenberger S. Bhas42 cell transformation assay as a predictor of carcinogenicity. Proc. 6th World Congress on Alternatives and Animal Use in the Life Sciences,Tokyo, Japan, Spec Issue. AATEX 2007, 14:519-521.
175. Prashant, R., Nambiar, P.R., Morton, D., 2013. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals Toxicol. Pathol. doi:10. 1177/0192623313477257. Epub 19 February 2013 (Accessed on 20.08.2013).
176. Pritchard J.B., French J.E., Davis B.J., Haseman J.K. The role of transgenic mouse models in carcinogen identification. Environ. Health Perspect. 2003, 111:444-454.
177. Rall D.P. Laboratory animal tests and human cancer. Drug Metabol. Rev. 2000, 32:119-128.
178. Reddy M.V., Sistare F.D., Christiansen J.S., Deluca J.G., Wollenberg G.K., Degeorge J.J. An evaluation of chronic 6- and 12- month rat toxicology studies as predictors of 2-year tumor outcome. Vet. Pathol. 2010, 47:614-629.
179. Robens, J.F., Calabrese, E.J., Piegorsch, W.W., Schueler, R.L., Hayes, A.W., 1994. Principles of testing for carcinogenicity. In: Hayes AW, (Ed.) Principles and Methods of Toxicology, third ed., Raven Press, New York, pp. 697-728.
180. Rhomberg L.R., Baetcke K., Blancato J., Bus J., Cohen S., Conolly R., Dixit R., Doe J., Ekelman K., Fenner-Crisp P., Harvey P., Hattis D., Jacobs A., Jacobson-Kram D., Lewandowski T., Liteplo R., Pelkonen O., Rice J., Somers D., Turturro A., West W., Olin S. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection. Crit. Rev. Toxicol. 2007, 37:729-737.
181. Schmid W. The micronucleus test. Mutat. Res. 1975, 31:9-15.
182. Semple R.K., Chatterjee V.K., O'Rahilly S. PPAR gamma and human metabolic disease. J. Clin. Invest. 2006, 116:581-589.
183. Serafimova, R., Fuart Gatnik, M., Worth, A., 2010. Review of QSAR models and software tools for predicting genotoxicity and carcinogenicity. JRC Publications, European Commission, Publications Office of the European Union. [Online] Available: http://publications.jrc.ec.europa.eu/repository/handle/111111111/14330. doi: 10.2788/26123 (Accessed on 21.05.2013).
184. Sistare F.D., Morton D., Alden C., Christensen J., Keller D., Jonghe S.D., Storer R.D., Reddy M.V., Kraynak A., Trela B., Bienvenu J.G., Bjurström S., Bosmans V., Brewster D., Colman K., Dominick M., Evans J., Hailey J.R., Kinter L., Liu M., Mahrt C., Marien D., Myer J., Perr R., Potenta D., Roth A., Sherratt P., Singer T., Slim R., Soper K., Fransson-Steen R., Stoltz J., Turner O., Turnquist S., van Heerden M., Woicke J., DeGeorge J.J. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 2011, 39:716-744.
185. Slikker W., Andersen M.E., Bogdanffy M.S., Bus J.S., Cohen S.D., Conolly R.B., David R.M., Doerrer N.G., Dorman D.C., Gaylor D.W., Hattis D., Rogers J.M., Setzer R.W., Swenberg J.A., Wallace K. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 2004, 201:226-294.
186. Soffritti M., Belpoggi F., Minardi F., Maltoni C. History and major projects, life-span carcinogenicity bioassay design, chemicals studied, and results. Ramazzini Foundation Cancer Program. Ann. N.Y. Acad. Sci. 2002, 982:26-45.
187. Solleveld H.A., McConnell E.E. The value and significance of life span and scheduled termination data in long-term toxicity and carcinogenesis studies. Toxicol. Pathol. 1985, 13:128-134.
188. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 2001, 34:146-152.
189. Steele V.E., Sharma S., Mehta R., Elmore E., Redpath J.L., Rudd C., Bagheri D., Sigman C.C., Keloff G.J. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell. Biochem. 1996, 63:29-53.
190. Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A.P., Vallot, F., Lafitte, J.J., Sculier, J.P., 2001. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J.18:705-719.
191. Storer R.D., Sistare F.D., Reddy M.V., DeGeorge J.J. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development. Toxicol. Pathol. 2010, 38:51-61.
192. Tennant R.W., French J.E., Spalding J.W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 1993, 103:942-950.
193. Tennan, R.W., Spalding, J., French, J.E., 1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and non carcinogens. Mutat. Res. 365, 119-127.
194. Thompson C.M., Haws L.C., Harris M.A., Gatto N.M., Proctor D.M. Application of the U.S. EPA mode of action framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium. Toxicol. Sci. 2011, 119:20-40. 10.1093/toxsci/kfq320.
195. Tice, R.R., Austin, C.P., Kavlock, R.J., Bucher, J.R., 2013. Improving the human hazard characterization of chemicals: a Tox21 update. [Online] Available at http://dx.doi.org/10.1289/ehp.1205784 (Accessed on 20.08.2013).
196. Tomatis L., Antero A., Wilbourn J., Shuker L. Human carcinogens so far identified. Jpn. J. Cancer Res. 1989, 80:795-807.
197. Tomatis, L., Huff, J., 2002. Evolution of research on cancer etiology. In: Coleman, W.B., Tsongas, J.G., (Eds.), The Molecular Basis of Human Cancer: Genomic Instability and Molecular Mutation in Neoplastic Transformation. Humana Press, Totowa, NJ, pp. 189-201.
198. U.S. EPA (U.S. Environmental Protection Agency), 1983. Good laboratory practice standards. (Source: 48 FR 52922, Nov. 29, 1983). 40 CFR Part 160.1-160.195. 7/1/2007.
199. U.S.EPA Guidelines for carcinogen risk assessment. Fed. Reg. 1986, 51:33992-34003.
200. U.S.EPA Proposed guidelines for carcinogen risk assessment. Fed. Reg. 1996, 61:17960-18011.
201. U.S. EPA, 1998a. Office of prevention, pesticide and toxic substances. health effect test guidelines OPPTS 870-4200: carcinogenicity. EPA 712-C-98-211.
202. U.S. EPA, 1998b. Office of prevention, pesticide and toxic substances. health effect test guidelines OPPTS 870-4300: combined chronic toxicity/carcinogenicity. EPA 712-C-98-212.
203. U.S. EPA, 1998c. Office of prevention, pesticide and toxic substances. health effects test guidelines, OPPTS 870.3100. Repeated dose 90-day oral toxicity study in rodents. EPA 712-C-90-199.
204. U.S. EPA, 1998d. Office of prevention, pesticide and toxic substances. health effects test guidelines, OPPTS 870.7800. Immunotoxicity. EPA 712-C-98-351.
205. U.S. EPA, 2000. Office of prevention, pesticide and toxic substances. health effects test guidelines, OPPTS 870.3050. Repeated dose 28-day oral toxicity study in rodents. EPA 712-C-00-366.
206. U.S. EPA, 2005a. Guidelines for carcinogen risk assessment. Risk Assessment Forum. U.S. Environmental Protection Agency. EPA/630/P-03/001F, U.S. Environmental Protection Agency, Washington, DC.
207. U.S. EPA, 2005b. Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. EPA/630/R-03/003F. [Online] Available at: http://www.epa.gov/cancerguidelines/guidelines-carcinogen-supplement.htm (Accessed on 19.08.2013).
208. U.S. EPA, 2005c. Science issue paper: mode of carcinogenic action for cacodylic acid (dimethylarsinic acid, DMAV) and recommendations for dose response extrapolation. [Online] Available at: http://users.physics.harvard.edu/wilson/arsenic/EPA%20DMA%20mode.pdf (Accessed on 19.08.2013).
209. U.S. EPA, 2013. Handbook for implementing the supplemental cancer guidance at waste and cleanup sites. [Online] Available at: http://www.epa.gov/oswer/riskassessment/sghandbook/chemicals.htm. (Accessed on 20.08.2013).
210. Vahle J.L., Finch G.L., Heidel S.M., Hovland D.N., Ivens I., Parker S., Ponce R.A., Sachs C., Steigerwalt R., Short B., Todd M.D. Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations. Toxicol. Pathol. 2010, 38:522-553.
211. Valerio L.G., Arvidson K.B., Chanderbhan R.F., Contrera J.F. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. Toxicol. Appl. Pharmacol. 2007, 222:1-16.
212. Van der Laan J.W., Lim B.S., Snodin D. Alternative models in carcinogenicity testing: a European perspective. Toxicol. Pathol. 2002, 30:157-159.
213. Van Oosterhout J.P.J., Van der Laan J.W., De Waal E.J., Olejniczak K., Hilgenfeld M., Schmidt V., Bass R. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul. Toxicol. Pharmacol. 1997, 25:6-17.
214. Vargas H.M., Amouzadeh H.R., Engwall M.J. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Exp. Opin. Drug Safety 2013, 12:91-102.
215. Walker J.D., Carlsen L., Hulzebos E., Simon-Hettich B. Global government applications of analogues, SARs and QSARs to predict aquatic toxicity, chemical or physical properties, environmental fate parameters and health effects of organic chemicals. SAR QSAR Environ. Res. 2002, 13:607-616.
216. Ward J.M. The 2-year rodent carcinogenesis bioassay-will it survive?. J. Toxicol. Pathol. 2007, 20:13-19.
217. Ward J.M. The roles of the toxicologic pathologist in cancer research. Toxicol. Pathol. 2010, 38:39-42.
218. Waters M.D., Jackson M., Lea I. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat. Res. 2010, 705:184-200.
219. Weisburger E.K. Techniques for carcinogenicity studies. Cancer Res. 1981, 41:3690-3694.
220. Weisburger J.H. Carcinogenicity and mutagenicity testing, then and now. Mutat. Res. 1999, 437:401-407.
221. Weisburger J., Weisberger E. Tests for animal carcinogens. Methods Cancer Res. 1967, 1:307-398.
222. Weisburger J.H., Williams G.M. The decision-point approach for systemic carcinogen testing. Food Chem. Toxicol. 1981, 19:561-566.
223. Weisburger J.H., Williams G.M. Carcinogen testing: current problems and new approaches. Science 1981, 214:401-407.
224. Weisburger, J.H., Williams, G.M., 2011. Topics in Toxicology: The distinction between genotoxic and epigenetic carcinogens and implication for cancer risk. In: Historical Perspectives. SOT 50th Anniv 1961-2011, Society of, Toxicology, Reston, VA, pp. 19-21.
225. Weisenthal L.M., Lippman M.E. Clonogenic and non-clonogenic in vitro chemosensitivity assays. Cancer Treat. Rep. 1985, 69:615-632.
226. Wells M.Y., Spencer Williams E. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies-implications for REACH. Regul. Toxicol. Pharmacol. 2009, 53:150-155.
227. Wexler, P., Fonger, G., Goshorn, J., 2011. The National Library of Medicine and its toxicology and environmental health information program. In: Historical Perspectives. SOT. 50th Anniv. 1961-2011, Society of, Toxicology, Reston, VA, pp. 1-3.
228. WHO (World Health Organization), 2007. PART 1: IPCS framework for analysing the relevance of a cancer mode of action for humans and case-studies Part 2: IPCS framework for analysing the relevance of a non cancer mode of action for humans. harmonization project document No. 4. [Online] Available at: http://www.inchem.org/documents/harmproj/harmproj/harmproj4.pdf (Accessed on 20.08.2013).
229. Whysner J., Ross P.M., Williams G.M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 1996, 71:153-191.
230. Williams G.M. Application of mode-of-action considerations in human cancer risk assessment. Toxicol. Lett. 2008, 180:75-80.
231. Williams, G.M., Iatropoulos, J.M., Enzmann, H.G., 2008. Principles of testing for carcinogenic activity. In: Hayes AW, (Ed.), Principles and Methods of Toxicology, fifth ed., CRC Press, Taylor & Francis, New York, pp.1265-1316.
232. Williams G.M., Weisburger J.H. Systematic carcinogen testing through the decision point approach. Ann. Rev. Pharmacol. Toxicol. 1981, 21:393-416.
233. Williams G.M., Weisburger J.H. Application of a cellular test battery in the decision point approach to carcinogen identification. Mutat. Res. 1988, 205:79-90.
234. Worth, A.P., 2010. The role of QSAR methodology in the regulatory assessment of chemicals. In: Puzyn, T., Leszczynski, J., Cronin, M.T.D., (Eds.), Recent Advances in QSAR Studies: Methods and Applications, Springer, Heidelberg, pp. 367-382.
235. Yamagiwa K., Ichikawa K. Experimental study of the pathogenesis of carcinoma. J. Cancer Res. 1918, 3:1-29.
236. Yamamoto Y., Moore R., Goldsworthy T.L., Negishi M., Maronpot R. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Toxicol. Sci. 2004, 108:59-68.
237. Young J.K., Hall R.L., O'Brien P., Strauss V., Vahl J.L. Best practices for clinical pathology testing in carcinogenicity studies. Toxicol. Pathol. 2011, 39:429-434.
238. Yu M.W., Chang H.C., Chang S.C., Liaw Y.F., Lin S.M., Liu C.J., Lee C.D., Lin S.D., Chen P.J., Lin S.C., Chen C.J. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 2003, 38:1393-1400.
239. Zwicki C.M., Cocke K.S., Tamura R.N., Holzhausen L.M., Brophy G.T., Bick P.H., Wierda D. Comparison of the immunogenicity of recombinant and pituitary growth hormone in rhesus monkeys. Fund. Appl. Toxicol. 1991, 16:275-287.